Last reviewed 2026-04-20 · How we verify

EDATREXATE

FDA-approved active Small molecule Quality 15/100

EDATREXATE is a edatrexate drug. It is currently FDA-approved.

At a glance

Generic name	EDATREXATE
Drug class	edatrexate
Target	Folylpolyglutamate synthase, mitochondrial, Dihydrofolate reductase, Dihydrofolate reductase
Modality	Small molecule
Therapeutic area	Oncology
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

EDATREXATE CI brief — competitive landscape report
EDATREXATE updates RSS · CI watch RSS

Frequently asked questions about EDATREXATE

What is EDATREXATE?

EDATREXATE is a edatrexate drug.

What drug class is EDATREXATE in?

EDATREXATE belongs to the edatrexate class. See all edatrexate drugs at /class/edatrexate.

What development phase is EDATREXATE in?

EDATREXATE is FDA-approved (marketed).

What does EDATREXATE target?

EDATREXATE targets Folylpolyglutamate synthase, mitochondrial, Dihydrofolate reductase, Dihydrofolate reductase and is a edatrexate.

Drug class: All edatrexate drugs
Target: All drugs targeting Folylpolyglutamate synthase, mitochondrial, Dihydrofolate reductase, Dihydrofolate reductase
Therapeutic area: All drugs in Oncology

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing